SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request</u>. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: Enstilar® (calcipotriene and betamethasone dipropionate) Foam (Non-Preferred)

| MEMBER & PRESCRIBER INFORMA | TION: Authorization may be delayed if incomplete. |
|---|---|
| Member Name: | |
| Member Sentara #: | Date of Birth: |
| Prescriber Name: | |
| Prescriber Signature: | Date: |
| Office Contact Name: | |
| Phone Number: | Fax Number: |
| DEA OR NPI #: | |
| DRUG INFORMATION: Authorization may | y be delayed if incomplete. |
| Drug Form/Strength: | |
| Dosing Schedule: | Length of Therapy: |
| Diagnosis: | ICD Code, if applicable: |
| Weight: | Date: |
| Length of Authorization: 4 weeks | |
| provided or request may be denied | at apply. All criteria must be met for approval. To ading lab results, diagnostics, and/or chart notes, must be |
| ☐ Member has diagnosis of plaque psoriasis | |
| AND | |
| \square Member is ≥ 18 years of age | |
| AND | |
| ☐ Member has had a trial on calcipotriene creat | m, ointment, or solution |

Use of samples to initiate therapy does not meet step-edit/preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.